Medication info
Rosuvastatin 20mg Tablets (Rosuvastatin Calcium)

Rosuvastatin 20mg Tablets (Rosuvastatin Calcium)

Prescription medicationTablet
Ingredient · strength
Rosuvastatin Calcium›20.8mg / 1 tablet
Manufacturer / importer
GL Pharma Co., Ltd.
Appearance
Pink circular film-coated tablets
Packaging
PTP - 28 tablets/PTP [(14 tablets/PTP x 2)]
Approval status
Active

MFDS item code 201904448 · Approved 2019.06.28 · Insurance code 649702270

Summary

Main use
Improves dyslipidemia, inhibits the progression of atherosclerosis, and reduces the risk of cardiovascular disease
Who uses it
Adults · Children
Adult dosage
1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this drug, and continue it throughout the treatment period. This drug may be taken at any time of day, with or without food. The initial dose is 5 mg once daily; if a greater reduction in LDL cholesterol is needed, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 mg once daily, which controls the condition in most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or longer according to LDL cholesterol levels, the treatment goal, and the patient's response; the dose may be increased to a maximum of 20 mg once daily. 3. Older adults: No dosage adjustment is necessary. 4. Patients with renal impairment: No dosage adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Exercise particular caution when administering 20 mg of this drug to patients with moderate renal impairment. 5. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this drug to patients with active liver disease. 6. Race: Because systemic exposure to this drug is increased in Asian patients, the recommended initial dose is 5 mg. Administration of the 40 mg dose is contraindicated. 7. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 mg. Administration of the 40 mg dose of this drug is contraindicated in some of these patients.
Children's dosage
2. Pediatric patients with heterozygous familial hypercholesterolemia (ages 10–17 years): The usual dosage range is 5 mg to 20 mg once daily. (There are no clinical data on doses higher than 20 mg in pediatric patients.) The dose should be adjusted individually according to the recommended treatment goal for each patient. The dose should be adjusted at intervals of 4 weeks or longer. The safety and efficacy in children under 10 years of age have not been established.

Ingredients

Manufacturer
GL Pharma Co., Ltd.

Efficacy & effects

Improves dyslipidemia, inhibits the progression of atherosclerosis, and reduces the risk of cardiovascular disease

  • Hypercholesterolemia
  • dyslipidemia
  • atherosclerosis
  • dysbetalipoproteinemia
  • increased high-sensitivity C-reactive protein
  • hypertension
  • low HDL-cholesterol levels
  • smoking
  • family history of early coronary artery disease
  • risk of stroke
  • risk of myocardial infarction
  • risk of arterial revascularization
View approved original text

This medication is primarily used as an adjunct in patients with primary hypercholesterolemia and mixed dyslipidemia when diet and exercise are insufficient. It is also beneficial in patients with homozygous familial hypercholesterolemia as an adjunct to diet or other lipid-lowering therapy. It effectively lowers total cholesterol and LDL-cholesterol levels, delaying the progression of atherosclerosis, particularly in pediatric patients aged 10 to 17 with heterozygous familial hypercholesterolemia. Additionally, it is used as an adjunct to diet in patients with primary dysbetalipoproteinemia. Furthermore, it helps reduce the risk of stroke, myocardial infarction, and arterial revascularization procedures in high-risk patients with cardiovascular disease risk factors. This medication is effectively used for dyslipidemia and cardiovascular disease risk reduction.

Dosage and Administration

Adult dosage

1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this drug, and continue it throughout the treatment period. This drug may be taken at any time of day, with or without food. The initial dose is 5 mg once daily; if a greater reduction in LDL cholesterol is needed, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 mg once daily, which controls the condition in most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or longer according to LDL cholesterol levels, the treatment goal, and the patient's response; the dose may be increased to a maximum of 20 mg once daily. 3. Older adults: No dosage adjustment is necessary. 4. Patients with renal impairment: No dosage adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Exercise particular caution when administering 20 mg of this drug to patients with moderate renal impairment. 5. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this drug to patients with active liver disease. 6. Race: Because systemic exposure to this drug is increased in Asian patients, the recommended initial dose is 5 mg. Administration of the 40 mg dose is contraindicated. 7. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 mg. Administration of the 40 mg dose of this drug is contraindicated in some of these patients.

Children's dosage

2. Pediatric patients with heterozygous familial hypercholesterolemia (ages 10–17 years): The usual dosage range is 5 mg to 20 mg once daily. (There are no clinical data on doses higher than 20 mg in pediatric patients.) The dose should be adjusted individually according to the recommended treatment goal for each patient. The dose should be adjusted at intervals of 4 weeks or longer. The safety and efficacy in children under 10 years of age have not been established.

Precautions

This drug should not be administered to certain patients. First, individuals allergic to any components of this drug should not take it. Patients with active liver disease or those with abnormally elevated liver enzyme levels in blood tests should also avoid this drug. Patients with muscle diseases or those taking the immunosuppressant cyclosporine should refrain from using this medication. Patients with severe renal impairment, women who are pregnant or breastfeeding, and fertile women who do not use appropriate contraception also should not use this medication. In particular, high dosing is prohibited in patients at greater risk of muscle disease. In addition, patients with genetic disorders related to lactose intolerance should avoid this medication. This drug may affect liver function; therefore, patients with a history of liver disease or those who consume alcohol excessively should undergo regular liver function tests. Symptoms such as muscle pain or weakness should be reported to healthcare providers immediately, and if necessary, blood tests should be conducted to check for muscle damage. Patients at high risk for severe muscle diseases require careful observation and testing before and after taking this medication. In cases of acute illness or severe conditions, this medication should be discontinued, and if severe muscle weakness occurs, it should be stopped immediately. This medication may interact with other drugs; therefore, it is essential to inform healthcare providers about any co-administered medications. Caution is advised when used with drugs that may increase the risk of muscle disease, and some drugs should be avoided in combination. This drug should not be used during pregnancy or breastfeeding, and women of childbearing potential should use appropriate contraception. There are no specific antidotes for overdose, so treatment should be symptomatic, and liver function and muscle enzyme tests are required. This medication may cause side effects such as dizziness, so caution is needed when driving or operating machinery. Finally, it is crucial to regularly check liver and muscle health status while on this medication and to consult healthcare providers immediately if any abnormal symptoms occur.

Side effects

Hypersensitivity reactions including angioedema, diabetes, headache, dizziness, constipation, nausea, abdominal pain, pancreatitis, pruritus, rash, urticaria, myalgia, myopathy, rhabdomyolysis, weakness, polyneuropathy, amnesia, peripheral neuropathy, myasthenia gravis, cough, dyspnea, diarrhea, ocular myasthenia, thrombocytopenia, jaundice, hepatitis, increased transaminases, Stevens-Johnson syndrome, eosinophilia with systemic symptoms drug reaction syndrome, lichenoid drug eruption, lupus-like syndrome, muscle rupture, arthralgia, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disturbances, interstitial lung disease, sexual dysfunction, gynecomastia, fatal and non-fatal liver failure, memory impairment, forgetfulness, amnesic syndrome, memory disorders, confusion, increased ALT, chest pain, muscle cramps, gout, erectile dysfunction, increased AST, numbness, sensory disturbances, chest discomfort, appetite loss, abdominal distension, syncope, generalized pain

Not everyone experiences these, and they can vary from person to person.

Storage

This medication may be sensitive to air or moisture, so it should be stored in a tightly closed container. The storage temperature should be kept between 1 to 30 degrees Celsius, and it is advisable to keep it in a cool place away from direct sunlight.

Appearance and packaging

Appearance

Pink circular film-coated tablets

Package unit

PTP - 28 tablets/PTP [(14 tablets/PTP x 2)]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.